drugset / Trial / NCT00550355

Dose-Escalating Multiple Dose Study of PD-0360324 in Combination With Methotrexate in Patients With Rheumatoid Arthritis

NCT00550355

Phase 1 Completed 78 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is designed to evaluate the safety and tolerability of multiple intravenously administered doses of PD 0360324 in patients with rheumatoid arthritis receiving methotrexate.

Timeline

Start
2007-08
Primary completion
2009-06
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject PD 0360324 Monoclonal antibody Intravenous

Indications